Regarding the urea cycle, pirfenidone, an ARG1 inhibitor, has shown positive results in patients with idiopathic pulmonary fibrosis, and therefore inhibition of ARG1 might be a valuable therapeutic aim in SSc [66]. Here, ARG1 is linked to pulmonary fibrosis.